Cardiac IVD Company Critical Diagnostics Continues Asia Pacific Push

Tools

New Presage® ST2 Distributors To Cover Australia, The Philippines, Malaysia and Singapore

Cardiac IVD Company Critical Diagnostics Continues Asia Pacific Push

Critical DiagnosticsDennis Dalangin, 877-700-1250VP Marketing

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, and makers of the Presage® ST2 Assay, today announced the addition of four new distributor relationships.

The Company has chosen Integrated Sciences as its exclusive distributor in Australia, United Laboratoriesin the Philippines and IDS Medical Systems/Malaysia in Malaysia and IDS Medical Systems/Singapore in Singapore.

“These new associations, together with our existing distribution partners, mean that some three billion people, or half the world’s population, will now have access to the Presage ST2 Assay,” notes James Snider, President of Critical Diagnostics. “And interest from distributors around the world continues to pour in.”

Headquartered in Sydney, with offices in the major cities of Australia, Integrated Sciences boasts greater 25 years experience in the Australian diagnostics and life sciences markets.

United Laboratories, founded in 1945, is the largest  in the Philippines and serves more than 1,000 cardiologists. Unilab also has significant and growing market share in the broader Asia-Pacific region.

Part of Hong Kong-based Li & Fung Group, IDS Medical Systems Malaysia and IDS Medical Systems Singapore, are integrated medical solutions providers focused on cardiovascular medicine. The company has over 20 years of experience in both Malaysia and Singapore.

Soluble ST2 has now been published in more than 100 peer-reviewed articles and scientific posters studying more than 35,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP.

Critical Diagnostics () develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. The Presage ST2 Assay has been CE Marked and cleared by the US FDA for use in risk stratification with chronic heart failure patients. Critical Diagnostics has exclusive worldwide rights to ST2 for the diagnosis and prognosis of cardiovascular disease.